Provider review
Andrew Meds Review: The Peptide Seller That Claims Nothing
Andrew Meds sells CJC-1295 with ipamorelin and a GHK-Cu cream, and its product pages promise nothing. No growth hormone, no body composition, no recovery, no anti-aging — the copy describes what is in the vial and tells you a provider decides whether it suits you. Across everything graded on this site that is close to unique, and it makes the two claims here impossible to overstate. What it does not do is describe the company: one click into the signup, the unsourced percentages start.
The only seller here whose peptide pages promise nothing — and whose signup screens, one click away, promise a great deal without sourcing any of it.
Worth trusting if
- You want product copy that describes what is in the vial rather than what it will do for you
- You want the GHK-Cu as a topical, which is how the molecule has actually been studied
- You want a published price ladder whose savings you can check, because all sixteen of its figures reconcile
Be skeptical if
- You want a certificate of analysis, because none is published for either product
- You want to know which pharmacy compounds it, or under which section
- You are taking the signup's percentages as findings, because none of them carries a source
Compounded only
Phase 2 only
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens andrewmeds.com. A link is not a recommendation to take anything.
Provenance
What Andrew Meds actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded GHK-Cu topical cream — $79 a month, falling to $49 on a twelve-month plan. Every prepay saving Andrew Meds advertises reconciles exactly against its monthly rate.
- Compounded CJC-1295 + Ipamorelin injection — $219 a month, or $159 on a twelve-month plan. The site files this product under "Anti-Aging" while claiming no anti-aging effect for it.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to Andrew Meds.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Andrew Meds’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded GHK-Cu topical creamGHK-Cu · Compounded (503A)Claim matches the trials
“GHK-Cu for your skin. Talk with a licensed provider to see if compounded GHK-Cu topical cream is the right fit for your skin goals. […] Compounded GHK-Cu is a topical cream applied to the skin. It is a copper peptide preparation used as part of a skin care routine, prescribed when a provider determines it is appropriate for you.”
Read on the Andrew Meds site, September 2026
Phase 2 only
What the trials show for GHK-Cu
- NCT07437586 — Phase 2, recruiting, n=60. Acute skin wound healing, recruiting. The completed GHK-Cu registry record is a 27-participant phase 4 study of facial skin quality, hydration and barrier function — a topical application, like this product.
The route is topical and the area is skin, which is the whole of what the GHK-Cu literature covers. Nothing here claims collagen synthesis, tissue regeneration or hair — the three things sellers of this molecule usually add and none can support. "Used as part of a skin care routine" is a description of how a product is used rather than a promise about what it does, and that is why there is nothing here to correct.1
Compounded CJC-1295 + Ipamorelin injectionCJC-1295 and ipamorelin · Compounded (503A)Claim matches the trials
“CJC-1295 with Ipamorelin. Talk with a licensed provider to see if this compounded injectable is the right fit for your goals. […] Compounded CJC-1295 with Ipamorelin is an injectable preparation combining two peptides in a single vial, prescribed when a provider determines it is appropriate for you.”
Read on the Andrew Meds site, September 2026
Phase 2 only
- NCT00267527 — Phase 2, terminated, n=120. The only registry record for CJC-1295. Terminated rather than completed, and it studied HIV patients with visceral obesity. Ipamorelin has no registry record of its own.
There is nothing here to check, and that is the finding. The page names the two peptides, says they arrive in one vial, and says a provider decides whether they suit you. It claims no growth hormone release, no body composition change, no sleep and no recovery — the four things every other seller of this stack claims. A statement that asserts no effect cannot reach past the evidence for one. Read that as a fact about the copy, not about the peptides: the only trial behind CJC-1295 was terminated, and ipamorelin has no registered trial at all.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on the site, and no compounding class is stated — the copy says "compounded" throughout and never cites 503A or 503B. What it does say is what the subscription includes: "Personalized Treatment Plans, Medication and Supplies, Shipping to Your Door", and that a plan "starts with a provider visit" conducted by video or online assessment. No medical group, prescriber or.
Read on the Andrew Meds site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency result, purity result or sterility result is published for either peptide. Andrew Meds makes no testing claim at all — which is consistent rather than evasive, since it also makes no efficacy claim, but it means a buyer has nothing to read about what is in the vial.
Read on the Andrew Meds site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Andrew Meds publishes both halves of its footprint, which is rare: asynchronous questionnaire care in 44 named states, and seven jurisdictions where a live consultation is required first — the District of Columbia, Kansas, Louisiana, Mississippi, New Mexico, Rhode Island and West Virginia. The two lists add to 51 and reconcile against each other. Its own intake then offers 50 states and does not include the District of Columbia, so a reader in the one jurisdiction it singles out cannot start.
Read the full licensing claim
"Prescribed Online" with a licensed Andrew Meds provider, by video visit or online assessment, with medical eligibility decided by that provider. No license number or prescriber name is published.
Read on the Andrew Meds site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its peptide pages assert no outcome at all. Across every provider graded on this site, that is close to unique — and it is why neither claim here can overstate its evidence.
- The GHK-Cu product is a topical and is described as one, with no hair claim attached — the route and the body area the literature actually covers.
- It says plainly that a provider decides eligibility, by video visit or online assessment, rather than implying the product is available on request.
Show 3 more
- Both peptides carry a published four-tier price ladder, visible before any account, and every advertised saving reconciles exactly against the monthly rate.
- It publishes which states get asynchronous care and which need a live visit — 44 and 7 by name, and the two lists reconcile.
- No FDA warning letter.
- No certificate of analysis, potency or purity result is published for either peptide.
- No pharmacy, laboratory, prescriber or medical group is named anywhere, and no compounding class is stated.
- The restraint stops at the product page. Its signup screens carry unsourced figures — an 18% average weight reduction, 93% keeping it off, a 94% chance of success — and two money-back guarantees its terms do not contain.
Show 4 more
- It files CJC-1295 with ipamorelin under "Anti-Aging" while claiming no anti-aging effect for it, so the navigation makes a claim the page declines to.
- The evidence behind that product is thin whatever the copy says: CJC-1295's only registry record was terminated, and ipamorelin has no registered trial at all.
- Its "Trustpilot Verified" testimonials match no Trustpilot profile — the review pages for both its domains do not exist.
- The District of Columbia is named among the states needing a live visit and cannot be selected in its intake.
Verdict
The bottom line
Judge this company on the half of it you are looking at. The peptide pages are the most restrained copy on this site and there is nothing in them to correct — no outcome is promised, so no outcome is overstated. Then open the signup, where the unsourced percentages live, and note that neither peptide has a certificate of analysis behind it and neither has a pharmacy named. The GHK-Cu cream is the safer of the two: a topical, for skin, which is what the trials studied.
Opens andrewmeds.com. A link is not a recommendation to take anything.
A page with nothing to correct
This site grades what a company says against what has been tested. Andrew Meds is the first provider on it that says almost nothing.
Here is the whole substantive claim for its growth-hormone product:
"Compounded CJC-1295 with Ipamorelin is an injectable preparation combining two peptides in a single vial, prescribed when a provider determines it is appropriate for you."
And its invitation:
"Talk with a licensed provider to see if this compounded injectable is the right fit for your goals."
No growth hormone release. No body composition. No sleep quality. No recovery. Every other seller of this exact stack graded here claims at least one of those, and most claim three at once.
The GHK-Cu page is the same shape:
"GHK-Cu for your skin. […] a copper peptide preparation used as part of a skin care routine."
A topical, for skin. That is where the GHK-Cu literature is — the completed registry record is a 27-participant study of facial skin quality and barrier function, applied to the skin. 1 No collagen synthesis, no tissue regeneration, and no hair, which is the word almost every seller of this molecule adds and none can support.
Full analysis — 3 more sectionsWhat that verdict does and does not mean · The other half of the company · What is not published
What that verdict does and does not mean
Both products are graded "claim matches the trials", and it is worth being exact about why.
A claim that asserts no effect cannot reach past the evidence for one. That is a statement about the copy. It is not a statement about the peptides.
The peptides are thin. CJC-1295's only registry record is terminated, and it studied HIV patients with visceral obesity rather than anyone buying online. 2 Ipamorelin has no registry record at all — half the vial is undescribed by any trial anywhere.
So: nothing here is misleading you, and nothing here is demonstrated either. Those are different failures and only one of them is Andrew Meds'.
The other half of the company
The restraint stops at the product page.
Our sibling cost site walked this company's signup and found a different voice entirely: "18% Average reduction in body weight", a claim that nine in ten patients call it the most effective weight-loss treatment they have tried, "93% Patients have kept the weight off", a "94% chance of treatment success" — and two money-back guarantees that appear nowhere in the terms of service.
None of those figures carries a source.
So a reader who judges Andrew Meds by its product pages is seeing the careful half of a company that has both.
What is not published
No certificate of analysis. No potency or purity result. No pharmacy. No laboratory. No prescriber or medical group. No compounding class — the copy says "compounded" and never names a section of the statute.
That last set is the ordinary state of this industry rather than anything specific to this company. It matters more here only because there is so little else to check: when a page makes no claim, the certificate is the one thing left that could tell you what you are buying.
Questions
Frequently asked questions
Does Andrew Meds say what its peptides do?
No, and that is the most unusual thing about it. Both peptide pages describe what is in the vial and say a provider decides whether it suits you. Neither claims growth hormone release, body composition, recovery, sleep or anti-aging — which is why neither claim can be graded as overstating anything.
Does that mean the peptides work?
No. The verdict grades the claim against the evidence, and there is no claim to grade. The evidence itself is thin: CJC-1295's only registered trial was terminated and studied HIV patients with visceral obesity, and ipamorelin has no registered trial at all.
Which of the two is better supported?
The GHK-Cu cream, comfortably. It is a topical applied to the skin, which is how the molecule has been studied — the completed registry record measured facial skin quality and barrier function in 27 participants. The injectable stack has one terminated trial behind one of its two ingredients.
Does it publish test results?
No. No certificate of analysis, potency or purity result appears for either product, and no pharmacy or laboratory is named. Since the pages make no efficacy claim, the certificate would be the only thing available to check — and it is not there.
Is the rest of the site as careful?
No. Its signup screens carry an 18% average weight reduction, a 93% maintenance figure and a 94% success chance, none sourced, plus two money-back guarantees the terms of service do not contain. The careful copy is on the product pages a reader sees first.
Glossary
Key terms
Show definitions
- Terminated trial
- A trial stopped before completion. It is neither a positive nor a negative result — the question was not answered, so no claim can rest on it.
- Topical
- Applied to the skin rather than injected. It matters for GHK-Cu because the human studies of that molecule were done on the skin, so an injected version is not covered by them.
Compare
Others selling what Andrew Meds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Andrew Meds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- US National Library of Medicine (2026). GHK-Cu — registry record, phase 2, recruiting, acute skin wound healing, NCT07437586; the completed GHK-Cu record is a 27-participant phase 4 study of facial skin quality, hydration and barrier function, and no registry record studies hair. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437586
- US National Library of Medicine (2026). CJC-1295 / growth hormone secretagogue — registry record, phase 2, TERMINATED, NCT00267527, in HIV patients with visceral obesity. No registry record exists for ipamorelin as an intervention. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00267527
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.